Clearmind Medicine Reflects on 2025 Progress
Ticker: CMND · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1892500
Sentiment: neutral
Topics: foreign-private-issuer, clinical-advancements, global-reach
TL;DR
Clearmind Medicine's 6-K details 2025 clinical wins and global expansion, setting stage for future growth.
AI Summary
Clearmind Medicine Inc. filed a Form 6-K on December 29, 2025, reporting on its activities for December 2025. The filing incorporates a press release dated December 24, 2025, titled "Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth," highlighting clinical progress and global expansion.
Why It Matters
This filing provides insight into Clearmind Medicine's strategic developments and clinical advancements during 2025, signaling potential future growth and market positioning.
Risk Assessment
Risk Level: medium — The filing is a routine report of foreign private issuer activities and does not contain specific financial performance data or significant new disclosures that would immediately alter risk perception, but it does indicate ongoing development in a volatile sector.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- December 24, 2025 (date) — Date of press release
- 2025 (date) — Year of review
- Vancouver, British Columbia (location) — Principal executive offices
FAQ
What specific clinical advancements were made by Clearmind Medicine in 2025?
The press release incorporated into the 6-K, dated December 24, 2025, is titled 'Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth,' indicating that clinical advancements are a key theme of the review, though specific details are not provided in the 6-K header.
What does 'Expanded Global Reach' refer to for Clearmind Medicine in 2025?
The press release mentioned in the 6-K highlights 'Expanded Global Reach' as a key achievement for Clearmind Medicine in 2025, suggesting international business development or market penetration efforts.
What is the filing type and reporting period for this document?
This is a Form 6-K, which is a Report of Foreign Private Issuer, filed as of December 29, 2025, for the month of December 2025.
Where are Clearmind Medicine's principal executive offices located?
Clearmind Medicine Inc.'s principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Does Clearmind Medicine file annual reports under Form 20-F or 40-F?
Clearmind Medicine Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 207 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2025-12-29 06:03:48
Filing Documents
- ea0270956-6k_clearmind.htm (6-K) — 10KB
- ea027095602ex99-1_clearmind.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-125574.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: December 29, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3